Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation
Reference7 articles.
1. Radiation therapy intensification for solid tumors: A systematic review of randomized trials;Yamoah;Int J Radiat Oncol Biol Phys,2015
2. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
3. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG oncology RTOG 0126 randomized clinical trial;Michalski;JAMA Oncol,2018
4. Impact of radiation therapy dose escalation on prostate cancer outcomes and toxicities;Zaorsky;Am J Clin Oncol,2018
5. Single-center trials tend to provide larger treatment effects than multicenter trials: A systematic review;Unverzagt;J Clin Epidemiol,2013
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Multiparametric Magnetic Resonance Imaging– Guided Dose-Escalated Radiation Therapy for Localized Prostate Cancer: A Prospective Phase 2 Trial;Practical Radiation Oncology;2023-11
2. Harnessing progress in radiotherapy for global cancer control;Nature Cancer;2023-09-25
3. Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations;International Journal of Radiation Oncology*Biology*Physics;2021-12
4. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer;Brachytherapy;2021-11
5. Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials;Prostate Cancer and Prostatic Diseases;2021-08-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3